Literature DB >> 34280060

Bridging the serodivide: attitudes of PrEP users towards sex partners living with HIV.

Mart Van Dijk1, John B F De Wit2, Thomas E Guadamuz3, Joel E Martinez4, Kai J Jonas1.   

Abstract

The introduction of biomedical HIV prevention methods, such as pre-exposure prophylaxis (PrEP), holds the potential to overcome the serodivide. We investigated the attitudes of PrEP users towards having sex with partners living with HIV. PrEP users in the Netherlands were recruited online and completed three questionnaires over a period of six months. We investigated changes over time in feelings of fear of HIV, comfort, and attitudes towards condom use when having sex with men living with HIV (MLHIV). A majority of PrEP users in our sample (up to 71.6%) had sex with MLHIV. Feeling comfortable to have sex with MLHIV did not change over time, but was already at a high level at T1. Most importantly, feeling safe not to use condoms with HIV-positive partners significantly increased, and did so in a rather short period of time after the onset of PrEP use (3-6 months). Taken together, the findings suggest that that PrEP may contribute to decreasing the serodivide between MSM rather quickly after the onset of PrEP use.

Entities:  

Keywords:  HIV stigma; PrEP; condom use; serodivide

Mesh:

Substances:

Year:  2021        PMID: 34280060     DOI: 10.1080/09540121.2021.1954588

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  2 in total

1.  PrEP Use in Times of COVID-19 in the Netherlands: Men Who Have Sex With Men (MSM) on PrEP Test Less for HIV and Renal Functioning During a COVID-19 Related Lockdown.

Authors:  Lizette C Krist; Hanne M L Zimmermann; Mart van Dijk; Sarah E Stutterheim; Kai J Jonas
Journal:  AIDS Behav       Date:  2022-05-16

2.  Using social media as a platform to publicly disclose HIV status among people living with HIV: Control, identity, informing public dialogue.

Authors:  Steven P Philpot; Dean Murphy; Garrett Prestage; Nathanael Wells
Journal:  Sociol Health Illn       Date:  2022-04-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.